Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple dosing-related claims do not match the label; notably one claim directly contradicts the labeled regimen (once daily vs once weekly). Several other counseling/regimen-structure details are unsupported or absent from the provided label sections.
Category Scores
Accurate Statements
Nascobal (cyanocobalamin) nasal spray dosing is usually given as a set schedule rather than as needed.
Supported by 2.2 Recommended Dosage (fixed recommended dosing; not PRN).
How often Nascobal is used can depend on lab results and how a clinician monitors B12 levels.
Supported by 2.3 Monitoring for Response and Safety and Dosage Modifications (monitor serum B12; consider increasing dose if levels decline; assess after dose adjustments).
Nascobal is taken correctly through the nose, not by mouth.
Supported by 2.2 (administer in ONE nostril) and 17 Patient Counseling Information (nasal administration instructions).
Unsupported Statements
After the initial period, the dosing is later switched to a less frequent maintenance schedule.
Not described in the provided label sections; 2.2 specifies an initial recommended dose of once weekly and 2.3 describes monitoring/discontinuation or indefinite continuation in pernicious anemia, not a maintenance schedule switch.
How often Nascobal is used can differ depending on whether a person is in the initial replacement phase versus maintenance.
No replacement vs maintenance phases are described in the provided label sections (2.2, 2.3).
How often Nascobal is used can depend on the cause of the B12 deficiency.
Partially addressed at most via treatment duration/discontinuation when risk corrected (2.3) and guidance to treat underlying correctible causes (2.4), but the claim specifically that dosing frequency depends on the cause is not supported.
Missed-dose instructions depend on the dosing schedule prescribed (daily versus maintenance).
No missed-dose instructions are present in the available provided label sections.
Improper use of Nascobal can reduce absorption.
The label mentions loss of medication due to hot foods causing nasal secretions and resulting loss of medication, but the explicit claim that improper use reduces absorption is not supported in the provided sections.
Contradictions
High
AI Statement
The typical adult regimen is one spray into one nostril once daily for a period of time.
Label Reference
2.2 Recommended Dosage states: one spray (500 mcg) administered in ONE nostril ONCE WEEKLY.
Important Omissions
The specific labeled administration instruction to give NASCOBAL at least one hour before or one hour after ingestion of hot foods or liquids, and defer use in patients with nasal congestion/allergic rhinitis/upper respiratory infections until symptoms subside.
Importance:
Moderate
Labeled monitoring and dosage modification timing details (obtain serum B12 and peripheral blood count one month after initiation; subsequently at 3 to 6 month intervals; consider increasing dose if serum B12 declines after one month; consider alternative therapy if persistently low; discontinue when corrected and no longer at risk; continue indefinitely in pernicious anemia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The once-daily dosing claim directly contradicts the labeled once-weekly regimen, which could lead to clinically significant dosing errors. Additional unsupported regimen-structure claims (replacement/maintenance switching) may further mislead dosing frequency.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contradictory dosing frequency (once daily vs label once weekly) plus multiple unsupported dosing-regimen and missed-dose claims.
Suggested Improvement
Replace any once-daily/maintenance-switch statements with the label’s fixed recommended dose (one spray 500 mcg in one nostril once weekly) and include the label-specific administration timing relative to hot foods/liquids and the monitoring/modification/discontinuation guidance from 2.3.